Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Insights and Forecast to 2028

Eptacog alfa (activated) is a recombinant activated factor VII (rFVIIa) used for the treatment and prevention of bleeding episodes in patients with congenital hemophilia with inhibitors.
Market Analysis and Insights: Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market
Due to the COVID-19 pandemic, the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 60 KIU accounting for % of the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Bleeding segment is altered to an % CAGR throughout this forecast period.
China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size is valued at US$ million in 2021, while the US and Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) include BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols and Biogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Scope and Segment
Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
60 KIU
50 KIU
Segment by Application
Bleeding
Surgery Assisted
Glanzmann Plateletasthenia
Hemophilia B
Hemophilia A
Head Trauma
Others
By Company
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Suzhou Alphamab
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions